NEW YORK, May 27, 2016 /PRNewswire/ -- Pomerantz LLP
is investigating claims on behalf of investors of Jazz
Pharmaceuticals plc ("Jazz" or the Company) (NASDAQ: JAZZ).
Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com
or 888-476-6529, ext. 9980.
[Click here to join a class action]
The investigation concerns whether Jazz and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
On May 27, 2016, Bloomberg
reported that Jazz had received a subpoena from the U.S. Attorney
for the District of Massachusetts,
initially disclosed on May 10, 2016
in the Company's 10-Q for the quarter ended March 31, 2016, seeking documents related to the
Company's relationship with certain nonprofits that provide
financial assistance to patients. The Bloomberg
article described how Jazz and other pharmaceutical companies make
large contributions to copay charities that help patients afford
their products.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los
Angeles, is acknowledged as one of the premier firms in the
areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the
Pomerantz Firm pioneered the field of securities class actions.
Today, more than 80 years later, the Pomerantz Firm continues in
the tradition he established, fighting for the rights of the
victims of securities fraud, breaches of fiduciary duty, and
corporate misconduct. The Firm has recovered numerous
multimillion-dollar damages awards on behalf of class members. See
www.pomerantzlaw.com
CONTACT:
Robert S.
Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-jazz-pharmaceuticals-plc--jazz-300276235.html
SOURCE Pomerantz LLP